MiMedx Group (NASDAQ:MDXG) Price Target Lowered to $8.00 at Cantor Fitzgerald

MiMedx Group (NASDAQ:MDXG) had its target price cut by equities research analysts at Cantor Fitzgerald from $12.00 to $8.00 in a research report issued on Tuesday,Benzinga reports. The firm presently has an “overweight” rating on the stock. Cantor Fitzgerald’s price target would suggest a potential upside of 56.40% from the stock’s previous close.

Several other analysts have also weighed in on the company. Wall Street Zen raised MiMedx Group from a “buy” rating to a “strong-buy” rating in a report on Sunday, November 2nd. Weiss Ratings reiterated a “hold (c)” rating on shares of MiMedx Group in a research note on Monday, December 29th. Mizuho dropped their price objective on shares of MiMedx Group from $12.00 to $10.00 and set an “outperform” rating for the company in a research note on Wednesday, December 17th. Finally, Lake Street Capital decreased their target price on shares of MiMedx Group from $12.00 to $10.00 and set a “buy” rating on the stock in a research report on Tuesday, January 20th. Three analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $9.33.

MiMedx Group Stock Performance

Shares of MDXG traded down $0.01 during trading hours on Tuesday, reaching $5.12. 57,858 shares of the company traded hands, compared to its average volume of 991,009. The company has a debt-to-equity ratio of 0.07, a quick ratio of 3.95 and a current ratio of 4.41. The stock’s fifty day moving average is $6.05 and its 200 day moving average is $6.69. MiMedx Group has a 1-year low of $4.89 and a 1-year high of $8.50. The stock has a market cap of $757.53 million, a P/E ratio of 19.06 and a beta of 1.59.

Institutional Trading of MiMedx Group

A number of large investors have recently bought and sold shares of MDXG. Royal Bank of Canada lifted its stake in MiMedx Group by 1.4% in the first quarter. Royal Bank of Canada now owns 982,532 shares of the company’s stock valued at $7,466,000 after acquiring an additional 13,629 shares during the last quarter. AQR Capital Management LLC lifted its stake in MiMedx Group by 42.6% in the 1st quarter. AQR Capital Management LLC now owns 14,374 shares of the company’s stock valued at $109,000 after purchasing an additional 4,296 shares during the last quarter. Jacobs Levy Equity Management Inc. acquired a new stake in MiMedx Group in the 1st quarter valued at about $232,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in MiMedx Group by 5.8% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 73,518 shares of the company’s stock worth $559,000 after purchasing an additional 4,049 shares during the period. Finally, Millennium Management LLC increased its position in MiMedx Group by 93.9% during the first quarter. Millennium Management LLC now owns 1,230,984 shares of the company’s stock worth $9,355,000 after buying an additional 596,016 shares during the last quarter. 79.15% of the stock is owned by institutional investors.

MiMedx Group Company Profile

MiMedx Group, Inc is a biopharmaceutical company focused on the development, manufacture and marketing of regenerative biomaterial products derived from human placental tissues. The company’s core mission centers on harnessing the extracellular matrix and growth factors within amniotic and chorionic membranes to support wound healing and surgical applications. MiMedx’s product line leverages proprietary purification processes designed to retain native tissue properties while ensuring sterility and safety.

MiMedx’s principal offerings include amnion/chorion allografts branded under names such as EpiFix® and AmnioFix®, which are indicated for the treatment of acute and chronic wounds—including diabetic foot ulcers, venous leg ulcers and surgical site repair.